{"database": "lobbying", "table": "lobbying_activities", "rows": [[3599444, "9340f9a2-c55c-41c7-80d2-d4dda6fb4f34", "Q2", "CROSSROADS STRATEGIES, LLC", 400531586, "TAKEDA PHARMACEUTICALS AMERICA, INC.", 2025, "second_quarter", "HCR", "Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2025-07-19T12:57:36-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3599444"], "units": {}, "query_ms": 12.657184852287173, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}